The Ocular Oncology Program at Smilow Cancer Hospital cares for patients with benign and malignant tumors of the eye, the eyelids, and the orbit. It is one of only a few centers in the nation dedicated full-time to ocular oncology within a cancer hospital. As most cancers of the eye and orbit are rare, treatment at a center with extensive expertise and experience is important. Our ocular oncology team is dedicated to individualized and integrated care for each patient. The Ocular Oncology Program at Smilow collaborates with caregivers in other specialties including melanoma, breast cancer, neuro-oncology, radiation oncology, pediatric oncology, and lung cancer. We treat the following conditions: Tumors and cancers of the eyelids, conjunctiva, cornea, lacrimal gland, and orbit Intraocular tumors of the iris, ciliary body, choroid, retina and optic disc Ocular melanoma Retinoblastoma Ocular metastases Lymphoma Hemangioblastoma Hemangioma Astrocytoma Nevus von Hippel-Lindau Tuberous sclerosis Gliomas

Children are susceptible to all eye diseases that occur in adults, as well as additional diseases. We promote the science and art of pediatric eye care to improve the visual health of children. Our expertise includes evaluating and treating amblyopia, strabismus, double vision, and other ocular motility disorders that affect the muscles that control eye movement in children and adults. We focus on children’s eye health through prevention. We also provide care for adult patients with newly developed eye muscle problems related to illness, head trauma, or residual problems from childhood strabismus. We are the only pediatric ophthalmology and strabismus group in southern New England located within an academic medical center, providing our patients access to cutting-edge care and research to improve the outcomes of pediatric eye disease.

HEROS is Connecticut's first childhood cancer survivorship program. It is a positive, empowering program for young cancer survivors that focuses on screening and managing the potential long-term effects of childhood cancer treatment. HEROS provides education and guidance to give survivors the tools they need to maximize their health, quality of life, and longevity as early as six months to one year out from treatment. We see anyone diagnosed with childhood cancer at or before the age of 21. We follow our survivors for life, without the need to transition to another clinic. Our multidisciplinary team includes a pediatric oncologist, psychologist, pediatric nurse practitioner, nurse coordinator, and research coordinator.